Cyprotex to expand US-based facility

According to the company, in January 2012, the facility for Cyprotex’s US operations will be increased from 4,400 sq ft to 8,200 sq ft in order to meet the growing demand.

There has been a rise in demand in North America for Cyprotex’s services and an increasing worldwide demand for the specialty in vitro toxicology services, especially Cyprotex’s CellCiphr High Content Toxicology service provided by the Watertown facility.

Cyprotex Chief Executive Officer Tony Baxter said the need to expand the Watertown facility is the consequence of a series of successful strategic efforts.

"This new service opens new commercial possibilities for compounds that historically may have had to be discontinued from development. With this new technology, Cyprotex is bringing personalised medicine into discovery programmes," Baxter added.